• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

关于停药的相关内容

  [复制链接]
8778 15 老马 发表于 2013-5-14 07:55:26 |
老马  博士一年级 发表于 2013-5-14 08:04:04 | 显示全部楼层 来自: 浙江温州
摘要:这3名患者在取得稳定的分子学缓解之后(融合基因转阴PCRU)停用达沙替尼。1名患者复发,另外两名患者在1年后仍保持了PCRU。以前说过,达沙替尼确实可以提高免疫力,希望今后能获得更多的相关研究报告。, T# P' @3 F# P  _- h6 D7 q/ W; h
    关于这个研究值得注意的是,这三名患者都是服用格列卫失败后转用达沙替尼的,也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同,那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察,看看停用达沙替尼是否能持久不复发。: `" W/ ^" R/ |- _8 C

. ?+ F$ T4 m3 }3 a; O作者:来自澳大利亚
6 ]' v" j$ \- V/ ^7 H来源:Haematologica. 2011.8.9.5 ^7 ]3 S+ \: y; N
Dear Group,
2 ~( t8 n& `5 L9 Q! I0 R; T) d: ?3 a( S
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
9 I; s5 l& ^; stherapies. Here is a report from Australia on 3 patients who went off Sprycel
6 g3 F% R% v1 k5 x- K# d# c/ yafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
, u. O) @7 Y# D, r+ z# g3 l; [remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel6 t9 S5 }/ D2 e; A
does spike up the immune system so I hope more reports come out on this issue.
5 @5 H, N7 h; }
3 Y- l# ~  P& e3 R5 Z9 aThe remarkable news about Sprycel cessation is that all 3 patients had failed) B/ i4 T- N- v* }! o# X
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
5 J" G$ C$ E' W/ y9 m% ndifferent from the stopping Gleevec trial in France which only targets patients3 ~$ _5 @5 y" S% c
who have done well on Gleevec.4 p2 b  p! P# i$ a* g9 }
6 i- b; `8 H- e& w% N4 B
Hopefully, the doctors will report on a larger study and long-term to see if the
# E( e* C' `9 p9 z2 a3 l. _response off Sprycel is sustained.
. q8 X4 X; g: T: _% U5 j- i) k! f, J: f7 F, h% y
Best Wishes,
6 N- a" [1 f& v3 AAnjana/ W8 G* p9 @7 W/ x

. Q4 I, p% M/ L, c: |, W/ P
2 i/ c9 u/ l: Q( q( {9 y  F: T! j4 }5 V
Haematologica. 2011 Aug 9. [Epub ahead of print]% P. s- _; q7 f: P: ]; B1 g
Durable complete molecular remission of chronic myeloid leukemia following
5 s# m% q% B) P9 v. z& D- ?; X/ Ddasatinib cessation, despite adverse disease features.
) M% r- {4 A1 SRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.1 ]4 O" [) p( M9 B" J; n% q
Source
& k# o/ M1 F4 |$ d0 A0 J! SAdelaide, Australia;( z. p. C9 E% Z8 u

0 [0 k: t4 W6 D" c. x4 SAbstract
9 |1 C6 v0 X5 D3 V: @7 u- x7 c" MPatients with chronic myeloid leukemia, treated with imatinib, who have a. V1 N& u) v) J! @8 T- y
durable complete molecular response might remain in CMR after stopping
- F/ }  G' j3 ~, G& A$ [' n8 |treatment. Previous reports of patients stopping treatment in complete molecular
6 h4 u# s5 F/ |4 l7 Eresponse have included only patients with a good response to imatinib. We- Y3 v" _  z5 D& i0 `" t
describe three patients with stable complete molecular response on dasatinib
. q" X; U# G4 b, v0 Gtreatment following imatinib failure. Two of the three patients remain in
# K* s) n6 ]# K9 e) m: V) ncomplete molecular response more than 12 months after stopping dasatinib. In" O+ L4 p9 Q2 _- E7 ^* M
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to5 g- a7 `% U. e! l' T4 d
show that the leukemic clone remains detectable, as we have previously shown in
5 d# L! S. W# ]! x& ~; Rimatinib-treated patients. Dasatinib-associated immunological phenomena, such as" Z5 F" `+ |3 k3 {% g* F
the emergence of clonal T cell populations, were observed both in one patient8 ^2 S4 d' n; Y0 z. M$ m( P
who relapsed and in one patient in remission. Our results suggest that the
3 J/ b6 E; W7 O; p2 |' h0 Echaracteristics of complete molecular response on dasatinib treatment may be
+ d2 p7 ~: B  t3 S9 isimilar to that achieved with imatinib, at least in patients with adverse
9 F% L, F4 h. v/ w* q' edisease features.2 @3 J! p* [+ z7 t# }+ d( r
个人公众号:treeofhope

举报 使用道具

回复 支持 0 反对 1
老马  博士一年级 发表于 2013-5-14 08:04:25 | 显示全部楼层 来自: 浙江温州
摘要:(STIM试验为法国的格列卫停药试验。)这个研究中,患者先是取得了CMR(融合基因转阴),然后停用格列卫,而后复发。15名复发患者在重新服药后又一次取得了CMR,他们同意再次停药。
6 B6 e" G. D# \4 {; y    第一次CMR持续时间为31个月,然后患者停药,复发的中位时间为2.6个月,然后重新服用格列卫,中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后,患者同意再次停药,这次,15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR,而10名患者在停药中位时间2月后第二次复发。# B8 e, U1 [) n7 j
    请注意,这些患者都是在第一次CMR后停药然后又复发的患者。
& J8 p2 v' ~+ ~3 P
# q  ]* ~% A2 e" c! H0 `作者:来自法国STIM试验$ {! N- H! a8 q
来源:EHA 2011.6.会议摘要
个人公众号:treeofhope

举报 使用道具

回复 支持 0 反对 1
gjzlovemama  初中一年级 发表于 2013-5-14 23:45:09 | 显示全部楼层 来自: 山东滨州
很不错的文章,看来马老师家有考虑停药的想法了啊!祝福!

举报 使用道具

回复 支持 0 反对 1
jack_7777  禁止访问 发表于 2014-11-22 19:47:19 | 显示全部楼层 来自: 广东广州
提示: 作者被禁止或删除 内容自动屏蔽
签名被屏蔽
sdlclqm  大学一年级 发表于 2015-9-29 19:03:13 | 显示全部楼层 来自: 山东聊城
期盼易或特也能停药,但现在觉得是一个梦想!
monekyll  大学二年级 发表于 2015-10-2 12:44:50 | 显示全部楼层 来自: 广东
这个非常有意义的研究。能吃下来停会再吃,再停,那是天大的好事

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表